YURAK YETISHMOVCHILIGI BO‘LGAN BEMORLARNI MONITORING QILISHDA SUN’IY INTELLEKTNING O‘RNI
Abstract
yurak yetishmovchiligi surunkali va qaytalanuvchi kechishi, dekompensatsiya epizodlarining tez-tez takrorlanishi hamda qayta gospitalizatsiya xavfi bilan tavsiflanadi. Shu sababli bemorni faqat rejalashtirilgan qabulda baholash ko‘pincha klinik yomonlashuvni erta aniqlash uchun yetarli bo‘lmaydi. Sun’iy intellekt algoritmlari elektron tibbiy kartalar, EKG, ekokardiyografiya, laborator ko‘rsatkichlar, implantatsion qurilmalar, kiyiladigan sensorlar va uy sharoitida o‘lchanadigan fiziologik ma’lumotlarni birlashtirib, dekompensatsiya xavfini baholashda qo‘llanmoqda. Ushbu maqolada sun’iy intellektning yurak yetishmovchiligi monitoringidagi imkoniyatlari, klinik dalillari, cheklovlari va xavfsiz joriy etish tamoyillari tahlil qilinadi. Asosiy xulosa shundan iboratki, AI klinik qarorni almashtirmaydi. U bemorni ustuvorlashtirish, yashirin yomonlashuv belgilarini ajratish va masofaviy kuzatuv tizimining javob tezligini oshirish uchun yordamchi vosita sifatida qiymatga ega.
Downloads
References
1. European Society of Cardiology. 2026 ESC Guidelines for the management of heart failure. European Heart Journal. 2026.
2. European Society of Cardiology Working Group on e-Cardiology. Digital solutions to optimize guideline-directed medical therapy prescription rates in patients with heart failure. European Heart Journal Digital Health. 2024.
3. 2026 ESC Guidelines for the management of heart failure. Section 11.5 Telemonitoring.
4. Remote patient monitoring in heart failure: a systematic review, meta-analysis, and trial sequential analysis. 2025.
5. Application and potential of artificial intelligence in heart failure: past, present, and future. International Journal of Heart Failure. 2024;6(1):11–19.
6. Use of artificial intelligence in improving outcomes in heart disease: a scientific statement from the American Heart Association. Circulation. 2024.
7. AIM-POWER Trial. Digital platform to optimize guideline-directed heart failure therapy. 2025.
8. FDA. Good machine learning practice for medical device development: guiding principles. 2021.
9. McDonagh TA, Metra M, Adamo M, et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. European Heart Journal. 2021;42:3599–3726.
10. Koehler F, Koehler K, Deckwart O, et al. Efficacy of telemedical interventional management in patients with heart failure TIM-HF2. Lancet. 2018;392:1047-1057.
11. Abraham WT, Stevenson LW, Bourge RC, et al. Sustained efficacy of pulmonary artery pressure to guide adjustment of chronic heart failure therapy. Lancet. 2016;387:453-461.
12. Efficacy of pulmonary artery pressure monitoring in patients with chronic heart failure: a meta-analysis of three randomized controlled trials. European Heart Journal. 2023.
13. Lindenfeld J, et al. Haemodynamic-guided management of heart failure GUIDE-HF: a randomised controlled trial. Lancet. 2021;398:991-1001.
14. U.S. Food and Drug Administration. Good machine learning practice for medical device development: guiding principles. 2021.
